WHO ICTRP trial
A phase lb feasibility study of the combination of panobinostat and midostaurin…
NL-OMON29431 · Overview of Medical Research in the Netherlands (NL-OMON) · Recruiting
Key facts
| Trial ID | NL-OMON29431 |
|---|---|
| Public title | A phase lb feasibility study of the combination of panobinostat and midostaurin in recipients of allogeneic stem cell transplantation with Flt3-ITD AML |
| Scientific title | A phase lb feasibility study of the combination of panobinostat and midostaurin in recipients of allogeneic stem cell transplantation with Flt3-ITD AML |
| Primary sponsor | HOVON Data Center |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Conditions | Acute Myeloid Leukemia |
| Interventions | This is a dose-escalation study of midostaurin in combination with a fixed dose panobinostat in high allelic ratio FLT3-ITD positive AML. Patients will receive panobinostat (PNB) at a starting dose of 20 mg once a day three times a week… |
| Registration date | Jun 12, 2017 |
| Target size | 30 |
| Secondary IDs | NL6189;NTR6511;2017-002335-42 : HO148 AML |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: